vTv Therapeutics

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and the Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HIGH POINT, N.C., Dec. 15, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) today announced that the Phase 2 Elevage study of azeliragon in people with mild Alzheimer's disease and type 2 diabetes did not meet its primary objective of demonstrating an improvement in cognition as assessed by the 14-item Alzheimer's Disease Assessment Scale – Cognitive Subscale (ADAS-cog14) relative to placebo. The 6-month trial investigated the efficacy and safety of 5 mg azeliragon administered orally once daily compared to placebo in 43 people with mild probable Alzheimer's disease and type 2 diabetes. The azeliragon treated group (n=21) had a 1.8 point decline from baseline in ADAS-cog14 compared to a placebo (n=22) decline of 0.35. These differences were not statistically significant. Consistent with previous studies, azeliragon was generally well-tolerated with similar incidences of treatment-emergent adverse events overall and by system organ class in both treatment groups.

vTv Therapeutics Announces Topline Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer's Disease and Type 2 Diabetes

Mesoblast

Anavex Life Sciences

BioNTech SE

Eli Lilly

Eli Lilly (NYSE: LLY) shares are trading higher on Tuesday after the company announced it will acquire Prevail for total consideration of $26.50 per share in cash. The company also issued the fiscal year 2020 EPS and sales guidance above analyst estimates.

Why Mesoblast, Anavex And More Pharma Stocks Are Moving Today

HIGH POINT, N.C., Dec. 15, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC (“vTv”) has entered into a licensing agreement with Anteris Bio for worldwide rights to vTv's novel clinical-stage Nrf2 activator compound, HPP971. Anteris Bio, a newly-formed portfolio company of Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NIBR) Dr. Mark Fishman, will focus on developing HPP971 as a new therapy for the treatment of renal disease.

vTv Therapeutics Announces Licensing Agreement for Novel Nrf2 Activator to Anteris Bio

Solid Biosciences

SELLAS Life Sciences Group

Tv Therapeutics (NASDAQ: VTVT) shares were trading higher on Friday after the company said its Phase 2 Simplici-T1 study of TTP399 achieved the primary objective of a statistically significant reduction in HbA1c. Tv Therapeutics Inc operates in the United States health care sector.

Why 3 Health Care Stocks Are Moving: Tv Therapeutics, Solid Biosciences, Sellas Life Sciences

Shares of VTVT stock are taking off on Friday after vTv Therapeutics' parent company purchased 625,000 shares for $1.60 per share. The post VTVT Stock: Why vTv Therapeutics Is Soaring on Friday appeared first on InvestorPlace.

VTVT Stock: Why vTv Therapeutics Is Soaring on Friday

As of late, it has definitely been a great time to be an investor in vTv Therapeutics (VTVT).

vTv Therapeutics' (VTVT) Shares March Higher, Can It Continue?

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 817 world-class investment firms that we track and now have access to the collective wisdom contained in these filings, which are based on their September 30 holdings, data that is available nowhere else. Should you consider vTv Therapeutics Inc (NASDAQ:VTVT) for your portfolio? We'll look to this invaluable collective wisdom for the answer.

Where Do Hedge Funds Stand On vTv Therapeutics Inc (VTVT)?

HIGH POINT, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced it has entered into a common stock purchase agreement (“Purchase Agreement”) for up to $47 million with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor.

vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital

Can-Fite BioPharma Ltd.

Five Prime Therapeutics

GT Biopharma Inc

InflaRx

Tonix Pharmaceuticals Hld

Vaxart

With the pandemic drawing much attention toward biotech stocks, there are some interesting ideas among in the small-cap field, but only if you understand the severe risks involved. The post 7 Biotech Penny Stocks Worth a Gamble appeared first on InvestorPlace.

7 Biotech Penny Stocks Worth a Gamble

HIGH POINT, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter ended September 30, 2020, and provided an update on the progress of its clinical programs.

vTv Therapeutics Announces 2020 Third Quarter Financial Results and Update

HIGH POINT, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today reported baseline characteristics for the enrolled subjects in the ongoing Elevage clinical study of azeliragon as a potential treatment for mild Alzheimer's disease (AD) in people with type 2 diabetes (NCT03980730). The data demonstrate that the patients enrolled in Elevage (n=43) have similar baseline characteristics to those in the STEADFAST A-study type 2 diabetes (T2D) subgroup (NCT02080364) (n=47). As the company reported in October 2018, data from this subgroup demonstrated nominally significant differences favoring azeliragon compared with placebo on the ADAS-cog11, an instrument used to evaluate cognition. The goal of the Elevage study is to confirm the results of these retrospective analyses in a 6-month Phase 2 study prior to initiating a Phase 3 study.

vTv Therapeutics Presents Baseline Characteristics of the Enrolled Subjects in the Elevage Study Suggesting Comparability to the Post-Hoc Diabetes Subgroup of the Phase 3 STEADFAST Study

HIGH POINT, N.C., Oct. 29, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that it will make an oral presentation at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Digital Event on November 4, 2020. The presentation will provide a general study update and data on the baseline characteristics of patients enrolled in the ongoing phase 2 Elevage Study of azeliragon as a potential treatment for mild-probable Alzheimer's disease (AD) in adult patients who also have type 2 diabetes. Patient enrollment in the Elevage Study concluded as of September 2020 and vTv expects to report topline results in December 2020.

vTv Therapeutics to Present Study Update and Preliminary Data on Baseline Characteristics of Study Participants in Phase 2 Elevage Study Evaluating Azeliragon at 13th Clinical Trials on Alzheimer's Disease (CTAD) Digital Event

Data Reported at EASD Virtual Conference Demonstrate that TTP399 Did Not Increase Plasma or Urine Ketones, Avoiding a Key Limitation to the Development of Oral Adjunctive Therapies for T1D Data Reported at EASD Virtual Conference Demonstrate that TTP399 Did Not Increase Plasma or Urine Ketones, Avoiding a Key Limitation to the Development of Oral Adjunctive Therapies for T1D

vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 Diabetes

HIGH POINT, N.C., Sept.  15, 2020  (GLOBE NEWSWIRE) --  vTv Therapeutics Inc.  (Nasdaq: VTVT) announced the appointment of Edward P. Taibi, Executive Vice President of MacAndrews & Forbes Incorporated (“MacAndrews”), to the vTv Board of Directors. Effective August 31, 2020, Mr. Taibi will serve a term through the date of the next annual meeting of the Company’s stockholders.

vTv Therapeutics Announces Appointment of Edward P. Taibi to its Board of Directors

Gilead Sciences

Regeneron Pharmaceuticals

Takeda Pharmaceutical

Zoetis

A handful of pharmaceutical stocks have been on fire lately, but I'm writing for a "buy" prescription for five of the best names now.

5 of the Best Pharmaceutical Stocks to Buy Right Now

HIGH POINT, N.C., Aug.  03, 2020  (GLOBE NEWSWIRE) --  vTv Therapeutics Inc.  (Nasdaq:VTVT) today reported financial results for the second quarter ended June 30, 2020, and provided an update on the progress of its clinical programs.

vTv Therapeutics Announces 2020 Second Quarter Financial Results and Update

HIGH POINT, N.C., July  27, 2020  (GLOBE NEWSWIRE) --  vTv Therapeutics Inc  . (Nasdaq: VTVT) today announced that the Company will present at the upcoming 2020 Alzheimer's Association International Conference (AAIC), held virtually, July 27–31, 2020.

vTv Therapeutics to Present Additional Clinical Data from the STEADFAST Study of Azeliragon at the Virtual Alzheimer's Association International Conference

- Treatment with TTP399 resulted in significant improvements in HbA1c with reduction in insulin,  without increasing risk of hypoglycemia or diabetic ketoacidosis (DKA) -

vTv Therapeutics Presents Two Late-Breaking Poster Sessions on Simplici-T1 Study at the American Diabetes Association’s Virtual Sessions Supporting the Potential of TTP399 as First-in-Class Oral Adjunctive Therapy for Type 1 Diabetes Patients

HIGH POINT, N.C., May  22, 2020  (GLOBE NEWSWIRE) --  vTv Therapeutics Inc.  (Nasdaq:VTVT) today announced that it will host its 2020 Annual Meeting of Stockholders (the "Annual Meeting") as a virtual-only meeting that will be held via live audio webcast due to the public health and safety concerns related to the COVID-19 pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees, and others.

vTv Therapeutics Changes its 2020 Annual Meeting of Stockholders to Virtual Format

Is  (VTVT) Outperforming Other Medical Stocks This Year?

Has vTv Therapeutics (VTVT) Outpaced Other Medical Stocks This Year?

As of late, it has definitely been a great time to be an investor in vTv Therapeutics Inc. (VTVT).

vTv Therapeutics Inc. (VTVT) Shares March Higher, Can It Continue?

Company Announced Positive Results from Its Phase 2 Type 1 Diabetes Trial Showing that TTP399 Lowered HbA1C, Decreased the Use of Insulin for Patients and Increased Time in Range Company Announced Positive Results from Its Phase 2 Type 1 Diabetes Trial Showing that TTP399 Lowered HbA1C, Decreased the Use of Insulin for Patients and Increased Time in Range

vTv Therapeutics Announces 2019 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Steve Holcombe transitioned from telecom to biotech back when vTv Therapeutics Inc (NASDAQ: VTVT) was just a startup.

VTV Therapeutics 'Close To The Finish Line' On What FDA, Diabetes Patients Want: An Adjunct Therapy To Insulin

vTv Therapeutics: A Promising Small Molecule Drug Discovery Pick For 2020

Clovis Oncology

Eton Pharmaceuticals Inc

Immunomedics

Perrigo

Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.

5 Drug/Biotech Stocks Likely to Beat Q4 Earnings Estimates

News for vTv Therapeutics Stock (VTVT)